

<b>Notice of References Cited</b>		Application/Control No.	Applicant(s)/Patent Under Reexamination	
		10/518,988	LASKY, JOSEPH ALEXANDER	
Examiner		Art Unit		Page 1 of 2
CRAIG RICCI		4161		

**U.S. PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A US-2006/0154936	07-2006	Lasky, Joseph Alexander	514/252.18
B	US-			
C	US-			
D	US-			
E	US-			
F	US-			
G	US-			
H	US-			
I	US-			
J	US-			
K	US-			
L	US-			
M	US-			

**FOREIGN PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N	WO 99/03854	01-1999	PCT	Zimmerman et al	CO7D
O					
P					
Q					
R					
S					
T					

**NON-PATENT DOCUMENTS**

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
U	Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. <i>Am J Pathol</i> . 155(1):213-21, 1999.
V	Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. <i>Am Rev Respir Dis</i> . 144(2):291-6, 1991.
W	Bonner JC, Lindroos PM, Rice AB, Moomaw CR, Morgan DL. Induction of PDGF receptor-alpha in rat myofibroblasts during pulmonary fibrogenesis in vivo. <i>Am J Physiol</i> . 274(1 Pt 1):L72-80, 1998.
X	Espinosa RE, Edwards WD, Rosenow EC 3rd, Schaff HV. Idiopathic pulmonary hilar fibrosis: an unusual cause of pulmonary hypertension. <i>Mayo Clin Proc</i> . 68(8):778-82, 1993.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a))  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**

Application/Control No.

10/518,988

Applicant(s)/Patent Under

Reexamination

LASKY, JOSEPH ALEXANDER

Examiner

CRAIG RICCI

Art Unit

4161

Page 2 of 2

**U.S. PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
A	US-			
B	US-			
C	US-			
D	US-			
E	US-			
F	US-			
G	US-			
H	US-			
I	US-			
J	US-			
K	US-			
L	US-			
M	US-			

**FOREIGN PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N					
O					
P					
Q					
R					
S					
T					

**NON-PATENT DOCUMENTS**

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
U	Veelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J. 8(12):2129-38, 1995
V	Lasky JA, Tonthat B, Liu JY, Friedman M, Brody AR. Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats. Am J Respir Crit Care Med. 157(5 Pt 1):1652-7, 1998.
W	Hasselbalch HC. A possible role for ST1571 in the treatment of idiopathic myelofibrosis. Am J Hematol. 68(1):63-4, 2001.
X	Enson Y, Thomas HM 3rd, Bosken CH, Wood JA, Leroy EC, Blanc WA, Wigger HJ, Harvey RM, Cournand A. Pulmonary hypertension in interstitial lung disease: relation of vascular resistance to abnormal lung structure. Trans Assoc Am Physicians. 88:248-55, 1975.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a))  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.